Vistagen Therapeutics, Inc. quarterly report, Q2 FY2016

Full document

Vistagen Therapeutics, Inc. — Form 10-Q Summary

Reporting period: Quarter and six months ended September 30, 2015, corresponding to the second quarter of VistaGen’s fiscal 2016 year. The filing was signed November 16, 2015. Dollar amounts below are U.S. dollars.

Business context

VistaGen is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, orally available AV-101, was in Phase 2 development for treatment-resistant major depressive disorder (MDD). An NIH-funded Phase 2A study began in October 2015 and was expected to enroll up to 28 patients. The company also pursued stem-cell-based drug-rescue programs and exploratory regenerative-medicine research.

Financial performance and position

  • Revenue: None in the three- or six-month periods ended September 30, 2015 or 2014; the company reported no revenue-generating arrangements.
  • Quarterly results: Operating expenses were $5.39 million, including R&D of $1.66 million and G&A of $3.73 million. Net loss was $7.05 million; loss attributable to common stockholders, after preferred dividends and deemed dividends, was $8.55 million, or $5.26 per basic and diluted share.
  • Six-month results: Operating expenses were $7.21 million (R&D $2.03 million; G&A $5.18 million). Net loss was $36.57 million, versus $6.57 million in the prior-year period. Loss attributable to common stockholders was $38.54 million, or $24.21 per basic and diluted share.
  • Cash flow: Six-month operating cash use was $2.33 million, compared with $1.53 million a year earlier. Financing provided $2.95 million; investing cash flow was zero. Cash increased by $624,000 to $694,000.
  • Liquidity and liabilities: At September 30, cash was $694,000, current assets $1.80 million, current liabilities $2.35 million, and total liabilities $3.26 million. Total assets were $1.93 million and stockholders’ deficit was $1.32 million. The company said cash on hand was insufficient to fund planned operations for the next 12 months, including expected cash expenditures of approximately $6.0 million.
  • Debt restructuring: Approximately $17.2 million of debt and related obligations were converted into Series B preferred stock and, for part of the conversions, warrants. Remaining reported notes payable included $106,400 current and $31,400 non-current; the company also reported small capital-lease obligations.
  • Margins: Not meaningful because the company had no revenue.

Changes versus comparable periods

  • Six-month net loss increased substantially, primarily because of a $26.7 million non-cash loss on extinguishment of debt, compared with $2.37 million in the prior-year period. The debt conversions reduced near-term debt-service obligations but generated significant accounting losses because the fair value of securities issued exceeded the debt’s carrying value.
  • Quarterly R&D and G&A expense rose from $558,000 and $556,000, respectively, in the prior-year quarter. The filing attributed much of the increase to non-cash stock-based compensation and higher professional-service costs.
  • Six-month stock-based compensation was $3.77 million, versus $408,400 a year earlier. September grants of immediately vested warrants accounted for substantial expense, including $2.84 million in G&A and $852,200 in R&D.
  • Quarterly net interest expense fell to $12,200 from $605,600, largely following debt conversions. The prior-year quarter included a $1.30 million non-cash gain from a decrease in warrant liability; that liability was eliminated after warrant amendments in May 2015.

Outlook, risks, and unusual items

  • Management expected continuing losses and negative operating cash flows while advancing AV-101 and other research programs. It planned to manage costs and seek financing through securities offerings, collaborations, and grants; it stated an intention to complete additional financing arrangements before year-end 2015. No assurance was given that funding would be available on acceptable terms or at all.
  • Platinum had agreed to buy an additional $3.0 million of Series B preferred and warrants by October 15, 2015; $500,000 had been purchased by September 30. The company identified this commitment and potential strategic collaborations as possible funding sources, while warning that they might not meet its needs. It stated that failure to obtain additional financing could require reducing, deferring, or discontinuing research and could threaten its ability to continue as a going concern.
  • Series B preferred carried a 10% annual dividend payable in common shares upon conversion. At quarter-end, accrued dividends were reported as an $805,300 liability; the six-month income statement included $828,000 of preferred dividends and a $1.14 million deemed dividend. Series B shares were convertible into common stock at $7 per share, subject to stated terms and conditions.
  • The filing reported approximately 3.43 million Series B shares outstanding and 4.69 million outstanding common-stock warrants at September 30. Potentially dilutive securities were excluded from diluted loss per share because they were antidilutive. Further conversions, exercises, or financing could materially dilute common shareholders.
  • Key business risks include the unproven safety and efficacy of AV-101, clinical-trial and regulatory uncertainty, reliance on the NIH and other third parties, dependence on contract manufacturers, limited cash and financing access, competition, and intellectual-property risks. The filing said VistaGen had no legal proceedings as of the report date.
  • Management concluded disclosure controls and procedures were effective; it reported no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Whether the additional financing commitments and subsequent fundraising actually closed, and whether proceeds were sufficient for the company’s stated cash needs.
  • Actual cash runway and spending against the approximately $6.0 million of expected cash expenditures over the following 12 months.
  • Enrollment, progress, safety, and results of the NIH-funded AV-101 Phase 2A study; the filing provided no trial results.
  • The terms, conversion status, dividend accrual, and potential dilution associated with Series B preferred stock and outstanding warrants.
  • The composition and non-cash nature of the $26.7 million six-month debt-extinguishment loss and the effect of the restructuring on future obligations.